To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Slides:

Advertisements

Similar presentations

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

Advertisements

Upon entry into the circulation, chylomicrons (containing apo B-48) produced by the small intestine, and VLDL (containing apo B-100) produced by the liver.

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients.

L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis James J. DiNicolantonio, PharmD, Carl J. Lavie,

AIM HIGH Niacin plus Statin to prevent vascular events

Copyright © 2012 American Medical Association. All rights reserved.

Lipoprotein(a), Cardiovascular Disease, and Contemporary Management

“Sick Fat,” Metabolic Disease, and Atherosclerosis

Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know Siddharth Singh, MD, Kymberly D. Watt,

Contemporary Diagnosis and Management of Unstable Angina

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Volume 148, Issue 4, Pages (April 2015)

“Sick Fat,” Metabolic Disease, and Atherosclerosis

J. Eric Ahlskog, PhD, MD Mayo Clinic Proceedings

Atrial Fibrillation in the 21st Century: A Current Understanding of Risk Factors and Primary Prevention Strategies Arthur R. Menezes, MD, Carl J. Lavie,

James H. O’Keefe, MD, Salman K. Bhatti, MD, Ata Bajwa, MD, James J

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Todd J.

Omega-3 Fatty Acids for Cardioprotection

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs Charles E. Argoff,

Combined Association of Cardiorespiratory Fitness and Body Fatness With Cardiometabolic Risk Factors in Older Norwegian Adults: The Generation 100 Study

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD, Matthew K. Ito,

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Can Vitamin D Deficiency Break Your Heart?

Peripheral Arterial Disease: Diagnosis and Management

Corticosteroids in the Treatment of Alcohol-Induced Rhabdomyolysis

My Approach to the Patient With Familial Hypercholesterolemia

Omega-3 Fatty Acid Therapy: The Tide Turns for a Fish Story

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Palliative Care and Hospice Programs

Topical Analgesics in the Management of Acute and Chronic Pain

Body Composition and Heart Failure Prevalence and Prognosis: Getting to the Fat of the Matter in the “Obesity Paradox” Carl J. Lavie, MD, Richard V.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit Barry A. Franklin, PhD Mayo.

James H. O'Keefe, M.D., Carl J. Lavie, M.D., Ben D. McCallister, M.D.

Meredith Kilgore, PhD, Paul Muntner, PhD, J

II. assessment of dyslipidemias

Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf

Contemporary Evidence-Based Guidelines

Rajiv Chhabra, MD, James H

Effects of Statins on Renal Function

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Peripartum Cardiomyopathy Presenting as an Acute Myocardial Infarction

Prediction of All-Cause Mortality by the Left Atrial Volume Index in Patients With Normal Left Ventricular Filling Pressure and Preserved Ejection Fraction

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis James J. DiNicolantonio, PharmD, Carl J. Lavie,

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

Rhanderson Cardoso, MD, Roger S

Medication Adherence: WHO Cares?

Adjunctive Therapies in the Treatment of Acute Coronary Syndromes

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

Effects of Niacin on Glucose Control in Patients With Dyslipidemia

Medical Treatment of Overactive Bladder: In Response

Ross Arena, PhD, PT, FAHA, Carl J. Lavie, MD Mayo Clinic Proceedings

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Guy S. Reeder, M.D. Mayo Clinic Proceedings

David E. Winchester, MD, David C. Wymer, MD, Roger Y

Autonomic Tone and Benefits of Cardiac Rehabilitation Programs

III. Treating dyslipidemias

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Guy S. Reeder, M.D., Raymond J. Gibbons, M.D. Mayo Clinic Proceedings

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

Acute and Chronic Seizures in Patients Older Than 60 Years

International Journal of Cardiology

Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients Peter P. Toth, MD, PhD, Sephy Philip,

Managing the Complications of Cirrhosis

Presentation transcript:

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James H. O'Keefe, MD Mayo Clinic Proceedings Volume 85, Issue 5, Pages 446-450 (May 2010) DOI: 10.4065/mcp.2010.0058 Copyright © 2010 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 1 Potential targets of lipid intervention. Low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein cholesterol (non–HDL-C) are recommended as the primary and secondary targets of therapy. Apo = apolipoprotein; IDL = intermediate-density lipoprotein; Lp(a) = lipoprotein(a); VLDL = very low-density lipoprotein. From J Am Coll Cardiol,13 with permission from Elsevier. Mayo Clinic Proceedings 2010 85, 446-450DOI: (10.4065/mcp.2010.0058) Copyright © 2010 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 2 In patients with stable chronic heart disease, levels of high-density lipoprotein cholesterol (HDL-C) continue to predict risk at any given level of low-density lipoprotein cholesterol (LDL-C) during treatment. Adapted from N Engl J Med,21 with permission. Copyright ©2007 Massachusetts Medical Society. All rights reserved. Mayo Clinic Proceedings 2010 85, 446-450DOI: (10.4065/mcp.2010.0058) Copyright © 2010 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 3 In patients who have had an acute coronary syndrome (ACS), elevated levels of triglycerides (TGs) (≥150 mg/dL; to convert to mmol/L, multiply by 0.0113) predict risk even in those with low-density lipoprotein cholesterol (LDL-C) levels lower than 70 mg/dL (to convert to mmol/L, multiply by 0.0259). HR = hazard ratio; MI = myocardial infarction; Ref = reference. Adapted from J Am Coll Cardiol,22 with permission from Elsevier. Mayo Clinic Proceedings 2010 85, 446-450DOI: (10.4065/mcp.2010.0058) Copyright © 2010 Mayo Foundation for Medical Education and Research Terms and Conditions